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1 |  INTRODUCTION
Early detection and confirmation of several genetic disor-
ders is of help to implement proactive measures, to improve 
the standard of care, to perform adequate genetic counseling 
and, in some diseases, to initiate therapy. Newborn screening 
(NBS) is the paradigm for presymptomatic detection of con-
ditions that could have devastating consequences without an 
Received: 10 May 2019 | Revised: 6 September 2019 | Accepted: 25 September 2019
DOI: 10.1002/mgg3.1016  
O R I G I N A L  A R T I C L E
Identification of 22q11.2 deletion syndrome via newborn 
screening for severe combined immunodeficiency. Two years’ 
experience in Catalonia (Spain)
Andrea Martin‐Nalda1  |   Anna M. Cueto‐González2 |   Ana Argudo‐Ramírez3 |    
Jose L. Marin‐Soria3 |   Monica Martinez‐Gallo4 |   Roger Colobran2,4 |   Albert Plaja2 |   
Neus Castells2 |   Jacques Riviere1 |   Eduardo F. Tizzano2,5 |   Pere Soler‐Palacin1
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
EF Tizzano and P Soler‐Palacin are both senior contributing authors. 
1Pediatric Infectious Diseases and 
Immunodeficiencies Unit, Department 
of Pediatrics, Vall d’Hebron Campus 
Hospitalari, Barcelona, Catalonia, Spain
2Department of Clinical and Molecular 
Genetics, Vall d’Hebron Campus 
Hospitalari, Barcelona, Catalonia, Spain
3Newborn screening laboratory, Section 
of Congenital Errors of Metabolism, 
Biochemistry and Molecular Genetics 
Department, Hospital Clinic, Barcelona, 
Catalonia, Spain
4Immunology Division, Vall d’Hebron 
Campus Hospitalari, Barcelona, Catalonia, 
Spain
5CIBERER (Biomedical Research Center 
Network in Rare Diseases), Barcelona, 
Spain
Correspondence
Andrea Martin‐Nalda, Pediatric Infectious 
Diseases and Immunodeficiencies Unit, 
Hospital Universitari Vall d’Hebron, 
Universitat Autònoma de Barcelona (UAB), 
Passeig de la Vall d’Hebron, 119‐129, 
08035 Barcelona, Spain.
Email: andmarti@vhebron.net
Abstract
Background: The current scenario of newborn screening is changing as DNA stud-
ies are being included in the programs of several countries. Severe combined im-
munodeficiency (SCID) disorders can be detected using quantitative PCR assays 
to measure T‐cell receptor excision circles (TRECs), a byproduct of correct T‐cell 
development. However, in addition to SCID, other T‐cell‐deficient phenotypes such 
as 22q11.2 deletion syndrome 22q11.2 duplication syndrome, CHARGE syndrome, 
and trisomy 21 are detected.
Methods: We present our experience with the detection of 22q11.2 deletion syn-
drome and 22q11.2 duplication syndrome in a series of 103,903 newborns included 
in the newborn screening program of Catalonia (Spain).
Results: Thirty newborns tested were positive (low TREC levels) and five were 
found to have copy number variations at the 22q11 region (4 deletions and 1 duplica-
tion) when investigated with array comparative genomic hybridization technology 
and MLPA.
Conclusion: Newborn screening for SCID enables detection of several conditions, 
such as 22q syndromes, which should be managed by prompt, proactive approaches 
with adequate counseling for families by a multidisciplinary team.
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early intervention and treatment. NBS, initially implemented 
in the United States in the 1960s (Guthrie, 1996), has been 
carried out in most developed countries for decades, origi-
nally for the detection and early treatment of phenylketon-
uria and now for other endocrine and metabolic diseases, 
mainly using tandem mass spectrometry. DNA testing has 
been recently included in the NBS programs of some coun-
tries. Since its initial implementation in Wisconsin in 2008, 
NBS using T‐cell receptor excision circle (TREC) assays to 
detect severe combined immunodeficiency (SCID) has been 
established in several geographic areas (eg, most American 
states (Kwan et al., 2014), Taiwan (Chien et al., 2017), Israel 
(Rechavi, Lev, Simon, Stauber, & Daas, 2017), Qatar, sev-
eral Canadian regions (King & Hammarström, 2018), and the 
Catalonian region in Spain), and has enabled early diagnosis 
and treatment, with better outcomes in SCID patients. Since 
2017, SCID is one of the 24 diseases included in the universal 
NBS program of the Catalonian Department of Health.
In addition to SCID, other T‐cell deficient conditions, 
such as 22q11.2 deletion syndrome (DS) (Barry et al., 
2017; Lingman Framme, Borte, Döbeln, Hammarström, 
& Oskarsdóttir, 2014), 22q11.2 duplication syndrome, 
CHARGE syndrome, and trisomy 21, can also be detected 
through NBS (Jyonouchi, Jongco, Puck, & Sullivan, 2017). 
22q11.2 DS is the most common and well‐described mi-
crodeletion syndrome, with a prevalence of around 1 in 
2000–4000 live births (Cancrini et al., 2014; Palmer et al., 
2018; Swillen & McDonald‐McGinn, 2015). The prev-
alence of 22q11.2 microdeletion and microduplication 
in the low‐risk population is around 1/992 and 1/850, re-
spectively (Grati, Molina Gomes, Ferreira, Dupont, & 
Alesi, 2015). 22q11.2 DS shows considerable inter‐ and 
intrafamilial clinical variability. Before the era of molec-
ular diagnoses, this condition was named according to the 
main clinical manifestations as velocardiofacial syndrome 
(OMIM 192430), conotruncal anomaly face syndrome 
(OMIM 217095), or DiGeorge syndrome (OMIM 188400), 
honoring Angelo DiGeorge, who first described this syn-
drome in 1965 (DiGeorge, 1965). Because of this high 
clinical variability, delays in the diagnosis are common, 
particularly in patients who do not manifest the character-
istic clinical symptoms (congenital heart disease, particu-
larly conotruncal anomalies, and palatal abnormalities) and 
those with a wide spectrum of manifestations that involve 
F I G U R E  1  SCID NBS diagnostic decision algorithm
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different medical specialties (Bassett, McDonald‐McGinn, 
Devriendt, Digilio, & Goldenberg, 2011; Cancrini et al., 
2014; Palmer et al., 2018; Swillen & McDonald‐McGinn, 
2015). An early diagnosis is associated with a better clini-
cal outcome, mainly because of the possibility of early pro-
tocolled care, including rehabilitation and adapted school 
programs, an appropriate vaccination schedule, and ade-
quate genetic counseling.
We present our experience with NBS for SCID through 
TREC quantification, highlighting early presymptomatic de-
tection of 22q11.2 deletion and duplication syndromes and 
the implications of proactive diagnostic and therapeutic mea-
sures, follow‐up, and counseling.
2 |  PATIENTS AND METHODS
In January 2017, NBS for SCID detection using the EnLite 
Neonatal TREC kit (Perkin Elmer, Turku, Finland) was uni-
versally implemented in Catalonia, Spain. A complex diag-
nostic decision algorithm was established, based on previous 
experience (Audrain, Léger, Hémont, Mirallié, & Cheillan, 
2018) (Figure 1). In 2018, the retest cutoff was changed from 
34 to 24 copies/µL, which decreased the retest rate from 
3.34% to 1.4%. All cases considered positive were referred 
to the reference unit within 14 days and confirmation exami-
nations were then carried out: flow cytometry of T, B and 
NK cells, including CD45+RO+/RA+, T CD4+CD8+, and 
HLA‐DR+, the T‐cell receptor repertoire, and lymphocyte 
mitogen proliferation. Depending on the results, a genetic 
panel for primary immunodeficiencies (PID) or consultation 
with a geneticist for clinical evaluation and array compara-
tive genomic hybridization (CGH) studies were then carried 
out.
We are currently using a custom‐designed next‐genera-
tion sequencing (NGS)‐based panel that targets 323 genes, 
including most of the known PID‐causing genes according 
to the 2015 IUIS (International Union of Immunological 
Societies) classification and other more recently described 
genes causing PID (Picard, Al‐Herz, Bousfiha, Casanova, 
& Chatila, 2015). This panel has been successfully used in 
our laboratory for genetic diagnosis of PID (Dieli‐Crimi, 
Martínez‐Gallo, Franco‐Jarava, Antolin, & Blasco, 2018). 
DNA copy‐number variations were investigated with array 
CGH using the CytoSure Constitutional v3 array 8  ×  60K 
(Oxford Gene Technology) according to the manufactur-
er's recommendations. Data analysis was performed with 
the Cytogenomics 2.1 software (Agilent company) with 
the ADM‐2 algorithm and a minimum of three consecutive 
probes to detect an anomaly. Array CGH was chosen de-
spite its higher cost because of the relatively small number 
of expected patients to test and because FISH and QF‐PCR 
techniques fail to detect some patients with nested deletions 
or copy number anomalies outside the 22q11.2 region.
3 |  RESULTS
To date, 130,903 newborns have been screened, and 30 have 
tested positive. Nine of the 30 were considered false‐positive 
cases (initial normal lymphocyte count with normalization of 
TREC values between 3 and 6  months of life), four cases 
had transient lymphopenia at the beginning with recovery in 
the following months, and three patients are currently under 
study. The remaining 14 were true‐positive cases, classified 
as follows: one SCID (calculated incidence, 1:130,903), two 
preterm infant, two chylothorax, three idiopathic lymphope-
nia, one Down syndrome, four 22q11.2 DS, and one 22q11.2 
duplication syndrome. These diagnoses are similar to those 
described in larger NBS SCID programs (Jyonouchi et al., 
2017).
Among the 22q11.2 DS and 22q11.2 duplication syn-
drome patients (Table 1), two had been diagnosed prenatally, 
whereas the remaining three were diagnosed postnatally 
using array CGH studies. This technique was used in patients 
who did not fulfill the SCID criteria, but showed low TREC 
levels and mild lymphopenia, with no signs or symptoms 
(no congenital heart abnormalities, characteristic phenotype, 
or hypocalcemia). No clinical cases of complete classical 
DiGeorge syndrome were found during the first months of 
life in our cohort.
4 |  DISCUSSION
We report our experience with NBS for SCID through TREC 
quantification, which enables detection of presymptomatic or 
oligosymptomatic cases of 22q11.2 deletion and duplication 
syndromes in addition to SCID.
Several publications have mentioned the benefits of an 
early diagnosis in patients with 22q11.2 DS (Barry et al., 
2017; Cancrini et al., 2014; Palmer et al., 2018; Swillen & 
McDonald‐McGinn, 2015), as a prompt intervention could 
anticipate complications. In addition to the patient's heart and 
kidney malformations, complications in the neonatal period 
can include severe hypocalcemia and immune dysfunction. 
Later, an apparently asymptomatic patient can reach school 
age with learning difficulties, speech problems, or velopha-
ryngeal insufficiency, and during adolescence and adulthood 
manifest neurobehavioral or psychiatric disorders that could 
have been prevented or ameliorated with a prompt diag-
nosis (Fiksinski, Schneider, Murphy, Armando, & Vicari, 
2018). Once 22q11.2 deletion or duplication syndrome has 
been established, multidisciplinary teams are required to 
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manage the various clinical manifestations and avoid further 
complications.
22q11.2 duplication syndrome involving the same region 
and genes as the deletion counterpart shows considerable 
clinical variability (milder clinical course with a spectrum 
of symptoms, ranging from normality to hypotonia, learning 
difficulties, psychomotor retardation, or intellectual disabil-
ity) and has a hereditary component. It is relatively common 
to secondarily discover a comparatively asymptomatic parent 
(Traynor, Butler, Cant, & Leahy, 2016). From the immuno-
logical viewpoint, the same evaluation is recommended in 
these patients as in those with the deletion syndrome (Traynor 
et al., 2016). Our patient with 22q11.2 duplication syndrome 
was clinically and immunologically indistinguishable from 
the 22q11.2 DS patients.
Two patients in our series had already received a pre-
natal diagnosis based on array CGH study, but the re-
maining three were only detected after TREC‐positive 
findings emerged on NBS. Despite the obvious benefit of 
the early diagnosis in these three patients, which enabled 
prompt initiation of protocolled care, avoidance of live 
vaccines when indicated (Lingman Framme et al., 2014), 
and opportune genetic counseling, the utility of NBS for 
22q11.2 deletion and duplication syndromes remains 
somewhat controversial (Bales, Zaleski, & McPherson, 
2010). It is known that several clinical manifestations 
of 22q11.2 DS such as hypocalcemia, immune dysfunc-
tion, learning difficulties, palate dysfunction, and feeding 
problems can benefit from early detection and a prompt 
intervention (Barry et al., 2017; Palmer et al., 2018) ul-
timately reducing morbidity. However, the 22q11.2 DS 
diagnosis through NBS places physicians in a clinical 
and ethical challenge, mainly regarding mild cases, as a 
curative treatment is not yet available. Thus, the parents’ 
anxiety and expectations must be considered when shar-
ing the diagnostic information. Trained psychologists and 
clinical geneticists should always be included in the mul-
tidisciplinary team for this condition. This approach has 
led to good results in terms of the parents’ acceptance of 
the diagnosis, appropriate early proactive follow‐up and 
adequate genetic counseling. Long‐term experience with 
these patients should determine the benefits and limita-
tions of this approach, as has been seen in cystic fibro-
sis (Mak, Sykes, Stephenson, & Lands, 2016), and will 
define whether this strategy should offered to other syn-
dromic patients detected through NBS screening, such as 
those with CHARGE syndrome.
Gradual implementation of SCID NBS with detection of 
22q11.2 deletion and duplication syndromes in other coun-
tries will provide additional observations on the baseline 
characteristics of these patients and improve our knowledge 
of the natural history of the disease, which is critical for de-
signing and validating future therapeutic measures.
To conclude, NBS using TREC assays enables a prompt 
diagnosis of patients with 22q11.2 DS. Array CGH analysis 
should be considered in all infants with non‐SCID T‐cell 
lymphopenia even in the absence of phenotypic abnormal-
ities and before next‐generation sequencing for PID. The 
percentage of 22q11.2 DS patients who show low TREC 
levels at birth is currently unknown, but it is likely far from 
100%; hence, clinical suspicion should remain as the main 
practice to achieve an early diagnosis in these patients.
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